Find clinical trials for Non-Hodgkin Lymphoma in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma

B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Leukemia

B-Cell Chronic Lymphocytic Leukemia

Lymphoid Leukemia

Mantle-Cell Lymphoma

Non-Hodgkin Lymphoma trials near Toronto, ON, CAN:

A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

The purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in adult participants with Relapsed or Refractory Non...

Active, not recruiting

Lymphoma, Non-Hodgkin

Drug: CC-96673

Phase 1

Celgene

Toronto, Ontario, Canada and 12 other locations

Locations recently updated

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling

Lymphoma, Non-Hodgkin

Drug: CC-99282

Drug: Tafasitamab

Phase 1, Phase 2

Celgene

Toronto, Ontario, Canada and 88 other locations

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting

Non Hodgkin Lymphoma

Drug: acalabrutinib

Drug: rituximab (IV)

Phase 1, Phase 2

Acerta Pharma

Toronto, Ontario, Canada and 31 other locations

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Active, not recruiting

Lymphoma, Non-Hodgkin

Drug: Fludarabine

Drug: JCAR017

Phase 2

Celgene

Toronto, Ontario, Canada and 37 other locations

A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

(CAR) T cells, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma.The study will consist of 2 parts: dose...

Active, not recruiting

Agressive Lymphoma

Diffuse-large B-cell Lymphoma (DLBCL)

Biological: CC-97540

Phase 1

Juno Therapeutics

Hamilton, Ontario, Canada and 13 other locations

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma...

Active, not recruiting

B-cell Non-Hodgkin Lymphoma

Drug: Polatuzumab vedotin

Drug: Mosunetuzumab (SC)

Phase 1, Phase 2

Roche

Hamilton, Ontario, Canada and 28 other locations

Locations recently updated

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO)

participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed folli...

Enrolling

Non-Hodgkin Lymphoma

Drug: Tocilizumab

Drug: Gemcitabine

Phase 3

Roche

Toronto, Ontario, Canada and 72 other locations

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

or Pola-R-CHP in participants with untreated diffuse large B-cell lymphoma (DLBCL). Evaluating the safety, preliminary activity, pharmacokin...

Active, not recruiting

B-Cell Lymphoma

Non-Hodgkin Lymphoma

Drug: Obinutuzumab (G)

Drug: Doxorubicin

Phase 1

Roche

Toronto, Ontario, Canada and 23 other locations

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK...

Enrolling

Non-Hodgkin's Lymphoma

Drug: Glofitamab

Drug: Obinutuzumab

Phase 1, Phase 2

Roche

Toronto, Ontario, Canada and 40 other locations

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)

lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).As of October 2022, no furt...

Enrolling

Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Biological: Brexucabtagene Autoleucel (KTE-X19)

Drug: Fludarabine

Phase 1, Phase 2

Gilead Sciences

Toronto, Canada and 36 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Non-Hodgkin Lymphoma in .css-epvm6{white-space:nowrap;}Toronto, ON

Related conditions:

Non-Hodgkin Lymphoma trials near Toronto, ON, CAN:

A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)

A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO)

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)

Find clinical trials for Non-Hodgkin Lymphoma in Toronto, ON